Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Early Phase 1WithdrawnNCT05416320

Wake Forest University Health Sciences

Overview

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.

Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)"

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Central Centrifugal Cicatricial Alopecia

Interventions

CalcipotriolDRUG

Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.

Subject's already prescribed drugDRUG

Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women who are eighteen years of age or older * biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV * must be on stable treatment without changes for at least 3 months * Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology. Exclusion Criteria: * Males

Locations (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States